Atreleuton

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524311

CAS#: 154355-76-7

Description: Atreleuton, also known as ABT-761, VIA-2291, A-85761; Abbott-85761, is a reversible 5-lipoxygenase inhibitor. Atreleuton exhibits potent and selective inhibition of leukotriene formation.

Chemical Structure

img
Atreleuton
CAS# 154355-76-7
Instruction

Theoretical Analysis

MedKoo Cat#: 524311
Name: Atreleuton
CAS#: 154355-76-7
Chemical Formula: C16H15FN2O2S
Exact Mass: 318.08
Molecular Weight: 318.370
Elemental Analysis: C, 60.36; H, 4.75; F, 5.97; N, 8.80; O, 10.05; S, 10.07

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 154355-75-6 (racemic)   154355-76-7    

Synonym: Atreleuton; ABT-761; ABT 761; VIA 2291; VIA-2291; VIA2291; A-85761; Abbott-85761.

IUPAC/Chemical Name: ((R)-3-(5-(p-Fluorobenzyl)-2-thienyl)-1-methyl-2-propynyl-1-hydroxyurea

InChi Key: MMSNEKOTSJRTRI-LLVKDONJSA-N

InChi Code: InChI=1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1

SMILES Code: C[C@H](C#Cc1ccc(s1)Cc2ccc(cc2)F)N(C(=O)N)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 318.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gaztanaga J, Farkouh M, Rudd JH, Brotz TM, Rosenbaum D, Mani V, Kerwin TC, Taub R, Tardif JC, Tawakol A, Fayad ZA. A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis. 2015 May;240(1):53-60. doi: 10.1016/j.atherosclerosis.2015.02.027. Epub 2015 Feb 24. PubMed PMID: 25752438.

2: Tardif JC, L'allier PL, Ibrahim R, Grégoire JC, Nozza A, Cossette M, Kouz S, Lavoie MA, Paquin J, Brotz TM, Taub R, Pressacco J. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307. doi: 10.1161/CIRCIMAGING.110.937169. Epub 2010 Feb 27. PubMed PMID: 20190281.

3: Qiu Y, Fort JJ, Trivedi J, Gerhardt AH, Mayer P, Briskin J, Schilling RJ. Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761. Drug Dev Ind Pharm. 2002 Mar;28(3):287-95. PubMed PMID: 12026221.

4: Barbosa MD, Arthur AS, Louis RH, MacDonald T, Polin RS, Gazak C, Kassell NF. The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage. Neurosurgery. 2001 Nov;49(5):1205-12; discussion 1212-3. PubMed PMID: 11846914.

5: Reid JJ. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. PubMed PMID: 11527015.

6: Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999 Jun;22(2):168-70. PubMed PMID: 10369259.

7: Connolly PJ, Wetter SK, Beers KN, Hamel SC, Chen RH, Wachter MP, Ansell J, Singer MM, Steber M, Ritchie DM, Argentieri DC. N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg Med Chem Lett. 1999 Apr 5;9(7):979-84. PubMed PMID: 10230624.

8: Wong SL, Cavanaugh JH, Qian J, Hansen R, Awni WM. Lack of cytochrome P450 1A2 interaction effect of ABT-761 on the pharmacokinetics of theophylline. Am J Ther. 1998 Sep;5(5):303-6. PubMed PMID: 10099073.

9: Wong SL, Kearns GL, Kemp JP, Drajesk J, Chang M, Locke CS, Dube LM, Awni WM. Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):715-9. PubMed PMID: 9923573.

10: Machinist JM, Mayer MD, Roberts EM, Surber BW, Rodrigues AD. Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab Dispos. 1998 Oct;26(10):970-6. PubMed PMID: 9763401.

11: Wong SL, O'Dea RF, Dube LM, Awni WM. Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers. J Clin Pharmacol. 1998 Jul;38(7):642-8. PubMed PMID: 9702850.

12: Lehnigk B, Rabe KF, Dent G, Herst RS, Carpentier PJ, Magnussen H. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J. 1998 Mar;11(3):617-23. PubMed PMID: 9596112.

13: Wong SL, Drajesk J, Chang MS, Witt G, Awni WM. Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers. Biopharm Drug Dispos. 1998 Apr;19(3):159-62. PubMed PMID: 9569998.

14: Wong SL, Drajesk J, Chang M, Lanni C, Witt G, Hansen R, Awni WM. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. Clin Pharmacol Ther. 1998 Mar;63(3):324-31. PubMed PMID: 9542476.

15: Harris RR, Komater VA, Marett RA, Wilcox DM, Bell RL. Effect of mast cell deficiency and leukotriene inhibition on the influx of eosinophils induced by eotaxin. J Leukoc Biol. 1997 Nov;62(5):688-91. PubMed PMID: 9365125.

16: Van Schoor J, Joos GF, Kips JC, Drajesk JF, Carpentier PJ, Pauwels RA. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med. 1997 Mar;155(3):875-80. PubMed PMID: 9117020.

17: Bell RL, Harris RR, Malo PE, Bouska JB, Shaughnessy TK, Hulkower KI, Brooks CD, Carter GW. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73. PubMed PMID: 9067325.

18: Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C, et al. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J Med Chem. 1995 Nov 24;38(24):4768-75. PubMed PMID: 7490726.